Thiol-disulphide homeostasis in patients with general anxiety disorder and panic disorder

Objective: The aim of this study was to evaluate the dynamic thiol-disulphide homeostasis as a novel oxidative stress parameter in newly diagnosed and medication-naive general anxiety disorder (GAD) and panic disorder (PD) patients. Method: Medication-naive patients with GAD (n=21) or PD (n=23) and healthy individuals (n=23) were enrolled. Patients were administered a sociodemographic form, Beck Depression Inventory, and Beck Anxiety Inventory. Routine biochemical parameters, native thiol, total thiol, and disulphide parameters were measured in all patients and healthy individuals. Results: The native thiol levels of the GAD and PD groups were found significantly lower than those of the control group (p

___

1. Remes O, Brayne C, van der Linde R, Lafortune L. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav 2016; 6:e00497.

2. Lader M. Generalized anxiety disorder: In: Stolerman IP, Price LH (editors). Encyclopedia of Psychopharmacology. Berlin Heidelberg: Springer, 2015; 699-702.

3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fifth ed. (DSM-5). Washington DC: American Psychiatric Publ., 2013.

4. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006; 97:1634-1658.

5. Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid Med Cell Longev 2009; 2:63-67.

6. Turell L, Radi R, Alvarez B. The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radic Biol Med 2013; 65:244-253.

7. Erel O, Neselioglu S. A novel and automated assay for thiol/ disulphide homeostasis. Clin Biochem 2014; 47:326-332.

8. Asoglu M, Kilicaslan F, Beginoglu O, Fedai U, Akil O, Celik H, Buyukaslan H. Thiol/disulphide homeostasis as a new oxidative stress marker in untreated patients with generalized anxiety disorder. Anadolu Psikiyatri Derg 2018; 19:143-149.

9. Kulaksizoglu B, Kulaksizoglu S. Thiol-Disulfide Homeostasis in Patients with Panic Disorder. Int J Clin Med 2017; 8:34-41.

10. Beck A, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571.

11. Hisli N. A study on the validity of the Beck Depression Inventory. Turkish Journal of Psychology 1988; 22:118-126 (Turkish).

12. Beck A, Epstein N, Brown G, Steer R. An Inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56:893-897.

13. Ulusoy M, Sahin NH, Erkmen H. Turkish version of the Beck Anxiety Inventory: psychometric properties. J Cogn Psychother 1998; 12:163-172.

14. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001; 158:1568-1578.

15. Graeff FG, Zangrossi H Jr. The dual role of serotonin in defense and the mode of action of antidepressants on generalized anxiety and panic disorders. Cent Nerv Syst Agents Med Chem 2010; 10:207-217.

16. Emhan A, Selek S, Bayazit H, Fatih Karababa I, Kati M, Aksoy N. Evaluation of oxidative and antioxidative parameters in generalized anxiety disorder. Psychiatry Res 2015; 230:806-810.

17. Ercan AC, Bahceci B, Polat S, Cenker OC, Bahceci I, Koroglu A, Sahin K, Hocaoglu C. Oxidative status and prolidase activities in generalized anxiety disorder. Asian J Psychiatr 2017; 25:118-122.

18. Bulut M, Selek S, Bez Y, Karababa IF, Kaya MC, Gunes M, Emhan A, Aksoy N, Sir A. Reduced PON1 enzymatic activity and increased lipid hydroperoxide levels that point out oxidative stress in generalized anxiety disorder. J Affect Disord 2013; 150: 829-833.

19. Bal N, Acar ST, Yazici A, Yazici K, Tamer L. Altered levels of malondialdehyde and vitamin E in major depressive disorder and generalized anxiety disorder. Dusunen Adam 2012; 25:206-211.

20. Kuloglu M, Atmaca M, Tezcan E, Ustundag B, Bulut S. Antioxidant enzyme and malondialdehyde levels in patients with panic disorder. Neuropsychobiology 2002; 46:186-189.

21. Gul I, Karlidag R, Cumurcu B, Turkoz Y, Kartalci S, Ozcan AC, Erdemli ME. The effect of agoraphobia on oxidative stress in panic disorder. Psychiatry Investig 2013; 10: 317-325.

22. Herken H, Akyol O, Yilmaz HR, Tutkun H, Savas HA, Ozen ME, Kalenderoglu A, Gulec M. Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Hum Psychopharmacol 2006; 21:53-59.

23. Ersoy MA, Selek S, Celik H, Erel O, Kaya MC, Savas HA, Herken H. Role of oxidative and antioxidative parameters in etiopathogenesis and prognosis of panic disorder. Int J Neurosci 2008; 118:1025-1037.

24. Cameron OG, Smith CB, Lee MA, Hollingsworth PJ, Hill EM, Curtis G. Adrenergic status in anxiety disorders: Platelet alpha2- adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorders patients and in normal subjects. Biol Psychiatry 1990; 28:3-20.

25. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 2014; 24:R453-R462.

26. Brunelli E, Domanico F, La Russa D, Pellegrino D. Sex differences in oxidative stress biomarkers. Curr Drug Targets 2014; 15:811-815.

27. Pietraforte D, Straface E, Piscopo P, Vona R, Confaloni A. Sexrelated biomarkers in cardiovascular and neurodegenerative disorders. Ann Ist Super Sanita 2016; 52:230-239.
Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi-Cover
  • ISSN: 1018-8681
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1984
  • Yayıncı: Kare Yayıncılık